Advanced Therapies Congress 2026
Advanced Therapies Congress 2026 brought together a global community of people who are shaping how advanced therapies move from scientific promise to real‑world patient impact. This year’s conversations highlighted the realities of operating at global scale, the operational maturity required to support increasingly complex therapies, and the shared ambition across the field to build systems that can deliver life‑changing treatments reliably and safely to patients everywhere.
For Cryoport Systems, it was an honour to contribute to these discussions. Our work is rooted in supporting therapeutic developers as they navigate the operational and logistical challenges that emerge as programmes expand. Being deeply involved at this year’s event allowed us to engage directly with teams building the future of advanced therapies, while sharing our own experience in supply chain design, cryopreservation, BioServices and biostorage, and global logistics.
Throughout the week, our team had the opportunity to participate across multiple dimensions of the event, from partnering meetings and booth conversations to presenting a scientific poster, contributing to a panel discussion, and opening the conference with a keynote.
Our booth served as a central point of connection throughout the event, bringing together teams working on some of the most innovative and technically demanding programmes in the field. These conversations reflected the momentum across advanced therapies and the shared focus on designing supply chains that can support global scale from the earliest phases of development. Across formal partnering meetings and informal discussions, we were able to collaborate with developers, CDMOs, academic groups, and clinical partners who are all contributing to the next generation of therapies.
Events and Takeaways from Advanced Therapies Congress 2026
Keynote Address
Building Global Readiness: How Integrated Supply Chains Drive Standardisation & Scale
Alison Pritchard opened ATC 2026 with a keynote exploring what it takes for advanced therapies to transition from promising early‑stage science to globally accessible treatments. She outlined how globalisation is reshaping expectations for operational maturity, why fragmentation continues to undermine reliability, and how integrated, standardised supply chain infrastructure creates the foundation needed to support scale. Her remarks emphasised the increasing influence of operational design on patient access and the importance of building global readiness far earlier in the development process.
Panel Discussion
Harnessing Technological Innovation to Optimise Supply Chain and Logistics in Advanced Therapies
Alison Pritchard also joined a panel examining where digital tools and automation can genuinely support advanced‑therapy supply chains today. The discussion highlighted both the potential and the limitations of current infrastructure, the importance of early structural decisions such as fresh versus frozen material strategies, and the need for strong partnerships as programmes expand across regions. The panel provided an insightful view from industry experts of what innovation looks like in practice, and what still needs to be built before digital transformation can deliver its full value.
Scientific Poster Presentation
Preserved and Protected: Automated Closed-System Cryopreservation and Advanced Shipping Systems for Secure and Scalable CGT Supply Chains
Our scientific poster showcased how automated closed‑system cryopreservation, paired with rigorously validated shipping systems, strengthens consistency and supports scale for advanced therapy programmes, demonstrating how upstream process control and standardised logistics environments reduce variability, improve chain‑of‑custody integrity, and create a more robust foundation for both clinical and commercial operations. The poster generated thoughtful discussions with developers looking to build supply‑chain resilience.
Thank you to all who connected with us at Advanced Therapies Congress 2026
The discussions throughout the week reminded us how much momentum exists across this field, and how strongly the community is aligned on building the operational foundation needed to support global patient access. We’re proud to play a role in that progress and grateful for the chance to work alongside so many teams pushing advanced therapies toward broader patient impact. We look forward to continuing these conversations throughout the year.
-
Alison Pritchard
Vice President – Business Development, EMEA -
Lloyd Norris
Director – Business Development, EMEA -
Matthew Frazzetta
Vice President – Global Accounts, BioServices -
Dominic Clarke
Vice President – Technical Operations IntegriCell -
René Fekete
Director – Business Development – EMEA -
Romain Robert
Sr. Process Engineer MS&T -
Alice Bouchoms
PD/MSAT Expert
About Cryoport Systems
Cryoport Systems is a comprehensive supply chain partner for the life sciences industry focused on meeting the challenges of the global cell and gene therapy market. We excel in the specialized management of the biopharma supply chain through our comprehensive offerings in logistics, BioServices and biostorage, cryopreservation, and consulting. With our expansive platform and decades of temperature-controlled supply chain expertise, Cryoport Systems helps Enable the Outcome™ for advanced therapies programs, safely and securely guiding critical therapies to patients in need.
About the Conference
Advanced Therapies Congress is Europe’s largest cell and gene therapy conference and exhibition. The event is for the leaders of the world’s ATMP developers and their most senior executives in charge of the latest tech and strategies that are driving the industry forward.
Let’s Connect
Interested in setting up a time to talk with our team of experts? Looking to follow up on a recent presentation or booth conversation? We’d love to hear from you! Fill out the form below and our team will be in touch.